Certara® has appointed Dr. William Feehery as its new Chief Executive Officer and a member of the Certara Board of Directors, effective June 3, 2019.
Certara® a model-informed drug development, regulatory science, real-world evidence and market access services company has appointed Dr. William F Feehery as its new Chief Executive Officer and a member of the Certara Board of Directors, effective June 3, 2019.
Dr. Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group. Dr. Feehery also serves as a board member for West Pharmaceutical Services, a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Edmundo Muniz, who has served as Certara CEO since June 2014, will become a member of the Certara Board of Directors and Chair of the Board’s newly-formed Science Committee. During Dr. Muniz’ tenure as CEO, Certara has grown to become the world leader in model-informed decision support solutions for drug development, regulatory science and market/patient access.
Dr. William Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University, and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.
Sheri McCoy, Certara Chairman of the Board said “we are very pleased to welcome Bill to Certara. Bill’s broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth. We also want to thank Edmundo for the great work he has done.”
Dr. Feehery said, “I am excited to join Certara, a company that is reducing the cost, time, and risk of drug development. I could not have made a better choice than to join the company at this exciting time in its growth trajectory. The company has already had a significant positive impact, helping to bring safer and more effective new therapies to market efficiently. The healthcare field is ripe for accelerated innovation of this type and Certara is poised to lead the market.”